- Home
- NYXH vs CERS Comparison
NYXH vs CERS Comparison
Compare NYXH & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- CERS
- Stock Information
- Founded
- NYXH 2009
- CERS 1991
- Country
- NYXH Belgium
- CERS United States
- Employees
- NYXH N/A
- CERS N/A
- Industry
- NYXH Medical/Dental Instruments
- CERS EDP Services
- Sector
- NYXH Health Care
- CERS Technology
- Exchange
- NYXH Nasdaq
- CERS Nasdaq
- Market Cap
- NYXH 273.3M
- CERS 265.7M
- IPO Year
- NYXH 2021
- CERS 1997
- Fundamental
- Price
- NYXH $7.46
- CERS $1.28
- Analyst Decision
- NYXH Strong Buy
- CERS Strong Buy
- Analyst Count
- NYXH 4
- CERS 2
- Target Price
- NYXH $14.50
- CERS $3.50
- AVG Volume (30 Days)
- NYXH 49.7K
- CERS 899.5K
- Earning Date
- NYXH 08-18-2025
- CERS 08-05-2025
- Dividend Yield
- NYXH N/A
- CERS N/A
- EPS Growth
- NYXH N/A
- CERS N/A
- EPS
- NYXH N/A
- CERS N/A
- Revenue
- NYXH $4,716,818.00
- CERS $185,144,000.00
- Revenue This Year
- NYXH $209.22
- CERS $24.95
- Revenue Next Year
- NYXH $219.37
- CERS $11.88
- P/E Ratio
- NYXH N/A
- CERS N/A
- Revenue Growth
- NYXH N/A
- CERS 13.06
- 52 Week Low
- NYXH $5.55
- CERS $1.12
- 52 Week High
- NYXH $11.87
- CERS $2.39
- Technical
- Relative Strength Index (RSI)
- NYXH 46.80
- CERS 41.13
- Support Level
- NYXH $6.90
- CERS $1.25
- Resistance Level
- NYXH $7.60
- CERS $1.41
- Average True Range (ATR)
- NYXH 0.34
- CERS 0.07
- MACD
- NYXH -0.05
- CERS -0.01
- Stochastic Oscillator
- NYXH 38.10
- CERS 13.64
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.